Pathological evaluation of differentiated thyroid cancer in patients with positive serum thyroglobulin and negative iodine scan

被引:0
|
作者
Ansari, M. [1 ]
Babaei, A. A. [1 ]
Shafiei, B. [2 ]
Javadi, H. [3 ]
Assadi, M. [4 ]
Nabipour, I. [4 ]
Asli, I. N. [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Imam Hossein Hosp, Dept Nucl Med, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Taleghani Hosp, Dept Nucl Med, Tehran, Iran
[3] Golestan Univ Med Sci, GRCGH, Gorgan, Iran
[4] Bushehr Univ Med Sci, Persian Gulf Nucl Med Res Ctr, Bushehr, Iran
关键词
Differentiated thyroid cancer (DTC); Pathologic subtype; Papillary thyroid cancer (PTC); Follicular thyroid cancer (FTC); Positive thyroglobulin and negative iodine scan. (Tg plus /WBS-); WHOLE-BODY SCAN; POSITRON-EMISSION-TOMOGRAPHY; RADIOIODINE THERAPY; I-131; CARCINOMA; TG;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: There is no investigation that emphasizes the pathology of DTC (differentiated thyroid cancer) patients with positive Tg and negative iodine scan. The present study was performed to assess the pathology of these patients. MATERIALS AND METHODS: In this retrospective study, the records of 500 patients with differentiated thyroid cancer between June 2005 and November 2011 were assessed, and those patients who had elevated serum thyroglobulin (Tg) with a negative whole body I-131 scan (Tg+/WBS-) were included in the study. Patients were followed for clinical and pathological findings of thyroid cancer, including type, variant, local invasion and cervical lymph node metastasis, and serum Tg, TgAb, and TSH levels. RESULTS: A total of 38 patients, including 31 (81.6%) females and 7 (18.4) males with a mean age of 44.2 +/- 15.6 years (range, 14 to 77 yrs) took part in the study. All 38 patients had the papillary type of differentiated thyroid cancer (PCDTC), and none had the follicular type of differentiated thyroid cancer (FCDTC). For the variant type of PTC in 16 patients, it was found that 7 were classic type (43.8%), 7 were follicular type (43.8%), and 2 were tall cell (12.4%) for papillary thyroid cancer. In 22 patients no distinct variant had been reported. CONCLUSIONS: This report demonstrated that all of the 38 patients were PTC (100%), which is different from other previous studies. It may be concluded that the overall pathologic subtypes changes of DTC could mainly be due to the iodine fortification program in various geographic regions. The relationship between DTC pathologic subtypes and frequency of Tg+/WBS-condition was difficult to assess in this work. Therefore, further studies are required to evaluate this issue.
引用
收藏
页码:1925 / 1929
页数:5
相关论文
共 50 条
  • [31] Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer:: preliminary results
    Martin, Tomas
    Torres, Alberto
    Cambil, Teresa
    Castro, Juan
    [J]. MEDICINA CLINICA, 2008, 131 (11): : 435 - 435
  • [32] Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan
    Rubello, D
    Saladini, G
    Carpi, A
    Casara, D
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2000, 54 (06) : 337 - 344
  • [33] The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer
    Li, Sha
    Ren, Chutong
    Gong, Yi
    Ye, Fei
    Tang, Yulong
    Xu, Jiangyue
    Guo, Can
    Huang, Jiangsheng
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [34] Treatment of iodine-negative thyroglobulin-positive thyroid cancer:: differences in outcome in patients with macrometastases and patients with micrometastases
    Kabasakal, L
    Selçuk, NA
    Shafipour, H
    Ozmen, O
    Onsel, C
    Uslu, I
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (11) : 1500 - 1504
  • [35] Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases
    Levent Kabasakal
    Nalan Alan Selçuk
    Hojjet Shafipour
    Ozlem Ozmen
    Cetin Onsel
    Ilhami Uslu
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : 1500 - 1504
  • [36] Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    Momesso, Denise P.
    Tuttle, R. Michael
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (06): : 2115 - 2116
  • [37] Letter to the Editor: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    Giovanella, Luca
    Cosma, Chiara
    Plebani, Mario
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (06): : 2113 - 2114
  • [38] How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level
    Elisei, Rossella
    Agate, Laura
    Viola, David
    Matrone, Antonio
    Biagini, Agnese
    Molinaro, Eleonora
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2014, 43 (02) : 331 - +
  • [39] Is there any venous gradient in serum thyroglobulin levels in patients with differentiated thyroid cancer?
    Gulben, K.
    Berberoglu, U.
    Uluocak, A.
    [J]. NEOPLASMA, 2010, 57 (03) : 260 - 263
  • [40] Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases
    Filesi, M
    Signore, A
    Ventroni, G
    Melacrinis, FF
    Ronga, G
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (09) : 1542 - 1546